Fisken J, Roulston J E, Sturgeon C, Badley R A, Jönrup I, Aspinall L, Leonard R C
University Department of Clinical Biochemistry, Royal Infirmary, Edinburg, UK.
Br J Cancer. 1993 May;67(5):1065-70. doi: 10.1038/bjc.1993.195.
We assayed serum HMFG2 in serial samples from 215 primary epithelial ovarian cancer patients using an 'in-house' single determinant ELISA, 45% of patients with stage I, 54% with stage II, 61% with stage III and 75% with stage IV disease had elevated serum HMFG2. Post-operative levels were significantly related with residual tumour volume (P < 0.005), and fell in the majority of responders, although the association with response to first-line chemotherapy was not significant. HMFG2 had a sensitivity of 50% specificity of 83%, accuracy of 61%, PVP of 86% and PVN of 45% for disease at second-look laparotomy. Serial levels gave a lead time to clinical relapse in 47% of patients who responded to therapy, including one patient with negative CA125 levels. HMFG, paralleled CA125 in many respects, although it was elevated in fewer patients. In a stepwise discriminant analysis, HMFG2 added to the discrimination of CA125 (r = 0.183, P < 0.005), although additional accurate information was only given in patients with advanced poorly differentiated serous cystadenocarcinoma. Given that HMFG2 is expressed in few patients who are CA125 negative it is unlikely that it will have a significant clinical impact upon patient management.
我们使用一种“内部”单决定簇酶联免疫吸附测定法（ELISA）检测了215例原发性上皮性卵巢癌患者系列样本中的血清HMFG2。I期患者中有45%、II期患者中有54%、III期患者中有61%以及IV期患者中有75%的血清HMFG2升高。术后水平与残留肿瘤体积显著相关（P < 0.005），并且在大多数有反应者中下降，尽管与一线化疗反应的相关性不显著。对于二次剖腹探查时的疾病，HMFG2的敏感性为50%，特异性为83%，准确性为61%，阳性预测值为86%，阴性预测值为45%。系列水平在47%对治疗有反应的患者中为临床复发提供了提前期，包括一名CA125水平阴性的患者。HMFG在许多方面与CA125平行，尽管其升高的患者较少。在逐步判别分析中，HMFG2增加了对CA125的判别能力（r = 0.183，P < 0.005），尽管仅在晚期低分化浆液性囊腺癌患者中提供了额外的准确信息。鉴于HMFG2仅在少数CA125阴性患者中表达，它不太可能对患者管理产生重大临床影响。
